Go to contents
Go to menu
°Ë»ö¾î ÀÔ·Â
Ȩ
·Î±×ÀÎ
Áñ°Üã±âÃß°¡
ENGLlSH
°í±Þ°Ë»ö
Àú³Îº°°Ë»ö
¿ø¹®Á¦°ø Àú³Îº°°Ë»ö
¿¬±¸ºÐ¾ßº° °Ë»ö
ÇÐȸ/Çùȸ Á¤º¸
Àú³Î Á¤º¸
Àú³Î Åõ°í ±ÔÁ¤
KMbase ¼Ò°³
°øÁö»çÇ×
¾÷µ¥ÀÌÆ® Á¤º¸
³» Á¤º¸
ÀúÀå ³í¹®
°ü½ÉºÐ¾ß ³í¹®
°ü½ÉÇÐȸ/ÇмúÁ¤º¸
¿ø¹®½Åû
°ü½ÉºÐ¾ß °ü¸®
½ºÅ©¸³Æ® ȯ°æ¿¡¼ Áö¿øµË´Ï´Ù.
³í¹®°Ë»ö
°í±Þ°Ë»ö
Àú³Îº°°Ë»ö
¿ø¹®Á¦°ø Àú³Î°Ë»ö
¿¬±¸ºÐ¾ßº° °Ë»ö
SITE LINK
PubMed
Google Scholar
NDSL
KISTI
KoreaMed
RISS
MEDLIS
Cross Check
°è¸íÀÇ´ë³í¹®Áý
( Keimyung Medical Journal )
: °Ë»ö°á°ú :
22
  
°Ë»ö°á°ú¸ðµÎ¼±ÅÃ
1
¿¡¸®½º·ÎÆ÷¿¡Æ¾ Ä¡·á¿¡ ´ëÇÑ ÀúÇ×¼º
Poor Response to Erythropoietin Therapy
¾È±Ô¸®/Cu Rie Ahn
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 360 ~ 364
2
ÀçÁ¶ÇÕ ÀÎ ¿¡¸®½º·ÎÆ÷ÀÌ¿¡Æ¾ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼ÀÇ Ã¶ºÐ Ä¡·á
Iron Management During Recombinant Human Erythropoietin Therapy
Çϼº±Ô/Sung Kyu Ha
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 345 ~ 359
3
¸»±â ½ÅºÎÀüÁõ ȯÀÚ¿¡¼ Recombinent Human Erythropoie tinÀÇ ÀÓ»óÀû ÀÀ¿ë
Practical Consideration of Erythropoietin Therapy
¹æº´±â/Byung Kee Bang
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 342 ~ 346
4
ÀÚµ¿º¹¸·Åõ¼®
Automated Peritoneal Dialysis
ÀÌÈ£¿µ/Ho Yung Lee
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 333 ~ 341
5
º¹¸· Åõ¼®¾×
Peritoneal Dialysis Solutions
¹Ú¹Î¼±
ÀÌÀº¾Æ
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 326 ~ 332
6
Åõ¼®ÀÇ ÀûÀýµµ
Dialysis Adequacy
±èµµÇå/Do Heon Kim
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 322 ~ 325
7
Hemofiltration and Hemodiafiltration with On-line Prepared Fluid - Blood Purification Therapies for
...
Jorgen Hegbrant
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 318 ~ 321
8
Ç÷¾×Åõ¼®À» À§ÇÑ Ç÷°üÅë·ÎÀÇ °£È£
Nursing Care of Vascular Access
¾çÇýÁÖ/Hye Joo Yang
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 312 ~ 317
9
½ÇÆÐÇÑ Ç÷°üÁ¢±ÙÀÇ °ü¸®
Management of Failing Access for Hemodialysis
¹®Àμº/In Sung Moon
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 308 ~ 311
10
ÀÎÁ¶Ç÷°üÀ» ÀÌ¿ëÇÑ µ¿Á¤¸Æ·ç Á¶¼º¼ú°ú ÇÕº´Áõ
PTFE Graft and Complications
±èÀ¯¼±
±è¸í¼ö
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 304 ~ 307
11
Ç÷¾×Åõ¼®À» À§ÇÑ ÀÏÂ÷¼º µ¿Á¤¸Æ·ç
Primary Arteriovenous Fistula for Hemodialysis
Á¶¿øÇö
±èÅ¿Ï, ±èÇüÅÂ, ±èÇüÅÂ
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 292 ~ 303
12
Ç÷°üÁ¢±ÙÀÇ ÀϹÝÀû °íÂû
General Consideration of the Vascular Access
Á¶°æÀÏ
¹Ú¼º¹è
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 282 ~ 291
13
µ¿»êº´¿ø Åõ¼®½ÇÀÇ ¾à»ç¿Í ÇöȲ
The History and Present Status of Dong San Medical Center Dialysis Unit
±èÇöö/Hyun Chul Kim
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 279 ~ 281
14
Leiomyoma of the Female Urethra
Joo Yong Shin
Cheol Ho Sohn/Joo Yong Shin/Cheol Ho Sohn
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 275 ~ 278
15
¼³Ãø ±³Á¤¼ú¿¡ ÀÇÇÑ ¹Ý´ë±³ÇÕÀÇ Ä¡Çè 1·Ê
Treatment of Anterior Crossbite by Lingual Orthodontic Appliance: A case report
¹ÚÈ¿»ó
¹ÚÈ¿»ó
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 267 ~ 274
16
½ÇÇèÀû(ãùúÐîÜ) °³È¸ÃæÁõ(̳üîõùñø) Áø´Ü(òàÓ¨)¿¡ ÀÖ¾î¼ ¿©·¯ °¡Áö Ç׿ø(ù÷ê«)ÀÇ È¿¿ë¼º(üùéÄàõ)
Use of Various Antigens in the Diagnosis of Experimental Toxocariasis
È«ÀçÈÆ
È«ÀçÈÆ, ±èÇõÀÏ, ÁÖÁ¾À±
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 256 ~ 266
17
Epidemiological Studies of Clonorchis sinensis in the Vicinity of Cheongdo River, Kyungpook, Korea
Ki Woo Kwak
Dong Hak Shin/Chong Yoon Joo/Dong Hak Shin
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 231 ~ 255
18
ÃÑ´ã°üÀ» °áÂûÇÑ ÈòÁã Ç÷û ¹× °£ÀÇ Isocitrate Dehydrogenase Ȱ¼ºµµ¿Í ÃÑ´ãÁó»êÀÇ ³óµµ
Serum and Liver Isocitrate Dehydrogenase Activities and Total Bile Acids Concentrations in Common Bi
...
ÁÖÀÏ
°ûÃá½Ä
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 218 ~ 230
19
´ãÁó»ê ºÎÇÏ¿¡ ÀÇÇÑ ÈòÁã °£ÀÇ CholinesteraseÀÇ ÇÕ¼º ¾ïÁ¦
Repression of Rat Hepatic Cholinesterase by Bile Acid Load
¹Ú¼Ò°æ
°ûÃá½Ä
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 204 ~ 217
20
Àü½Å¸¶Ãë¿Í ôÃ߸¶Ãë ÇÏ¿¡ ÇÏÁö ¼ö¼ú½Ã ±¸Ç÷±â¿¡ ÀÇÇÑ Ç÷¿ªÇÐÀû º¯È
Hemodynamic Changes Associated with Tourniquet Use Under General or Spinal Anesthesia for lower Extr
...
±èÁø¸ð/Jin Mo Kim
ÀüÀç±Ô/µµÇö¿ì/ÃÖÀ±Á¤/±èÁø¸ð/ÀüÀç±Ô/µµÇö¿ì/ÃÖÀ±Á¤/Jae Kyu Cheun/Hyun Woo Do/Yoon Jeong Choi/Jin Mo Kim/Jae Kyu Cheun/Hyun Woo Do/Yoon Jeong Choi
°è¸íÀÇ´ë³í¹®Áý
1999³â 18±Ç 2È£ 190 ~ 203
1
2